Precision Oncology: Who, How, What, When, and When Not?

Area of Science:

• Oncology
• Genomics
• Molecular Biology

Background:

• Precision oncology, or molecular tumor profiling, is increasingly integrated into clinical practice.
• Genomic testing requires collaboration among stakeholders to ensure high-quality tissue samples and accurate next-generation sequencing (NGS) analysis.
• Clinicians must understand genomic variant types, NGS technology, and its limitations.

Purpose of the Study:

• To review the current landscape of precision oncology and genomic testing.
• To highlight the importance of multidisciplinary interpretation of genomic results for clinical decision-making.
• To discuss the role of molecular profiling in non-small cell lung cancer (NSCLC) and the implications of treatment resistance.

Main Methods:

• Literature review and synthesis of current practices in precision oncology.
• Discussion of next-generation sequencing (NGS) methodologies and interpretation challenges.
• Case example of non-small cell lung cancer (NSCLC) to illustrate genomic-guided treatment.

Main Results:

• Genomic data is crucial for optimal treatment of advanced non-small cell lung cancer (NSCLC).
• Resampling and retesting tumors, including liquid biopsies, are important after progression to guide subsequent treatment.
• Appropriate utilization of molecular profiling is key to maximizing its value and avoiding under- or over-treatment.

Conclusions:

• Precision oncology offers significant potential to improve patient outcomes through targeted therapies.
• Multidisciplinary input is essential for accurate interpretation and clinical application of genomic findings.
• Continued evolution of genomic techniques and cost-effectiveness will expand the use of molecular testing in oncology.